Search Clinical Trials
Sponsor Condition of Interest |
---|
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans...
National Human Genome Research Institute (NHGRI)
Heart Disease
Background:
The COVID-19 pandemic infected and killed African Americans at higher rates than other
Americans. Researchers want to understand why.
Objective:
This natural history study will look at how genetic, environmental, and social factors
may predict or affect COVID-19 in African Americans.... expand
Background: The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why. Objective: This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study. Eligibility: African Americans who were previously enrolled in GENE-FORECAST. Design: The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities. The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic. The clinic visit will last up to 4 hours. Participants will have a physical exam. They will have blood and urine tests. They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose. They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm. Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs. Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play. Type: Observational Start Date: Feb 2023 |
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Background:
COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the
number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood
cell that fights infections. With fewer lymphocytes, the body cannot effectively fight
back against SARS CoV-2,... expand
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more about how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system. Eligibility: Adults age 18 and older who either currently have COVID-19 or have recently recovered from it Design: Participants will give a blood sample. For this, a needle is used to collect blood from an arm vein. For participants who have a central line, blood will be collected through that instead. Participants medical records related to COVID-19 will be reviewed. Participants who have recovered from COVID-19 will be asked to undergo leukapheresis to collect white blood cells. For this, blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned to the participant through a needle placed in the other arm. This takes about 2-3 hours. Recovered participants may have material collected from inside the nostrils and/or rectum. This is done by gently rubbing the area with a sterile cotton swab. Recovered participants may have an echocardiogram to look at their heart. For this, a small probe is held against the chest to get pictures of the heart from different angles. This takes less than 30 minutes. Participation lasts 1-2 days on most cases and may be split in a few visits for recovered patients if leukapheresis and echocardiogram are done. ... Type: Observational Start Date: May 2020 |
Natural History Study of COVID-19 Using Digital Wearables
National Institute on Minority Health and Health Disparities (NIMHD)
COVID-19 Virus Disease
Background:
People with COVID-19 have varying degrees of illness. It can range from no or mild
symptoms to critical illness and death. Some people with COVID-19 have long-term effects
regardless of the severity of their disease initially. Researchers want to learn more to
see if they can better... expand
Background: People with COVID-19 have varying degrees of illness. It can range from no or mild symptoms to critical illness and death. Some people with COVID-19 have long-term effects regardless of the severity of their disease initially. Researchers want to learn more to see if they can better predict where a person may fall on the illness spectrum. Objective: To follow and record symptoms of COVID-19 to see how it progresses in people and why some people stay sick longer than others. Eligibility: People ages 18-65 who received a COVID-19 positive test result in the 72 hours before their enrollment in the study. Design: Participants will complete a 30-minute baseline survey. They will answer questions about themselves and their health. Participants will get a digital wristband and temperature sensor in the mail. They will get instructions on how to set up and wear the devices. They will download a mobile application on their phone. The app will collect data from the devices. Participants will wear the wristband and sensor every day for the first month. Then they will wear the devices for a total of 40 days over the next 5 months. On the days they wear the devices, they will answer a 2-question health survey via the app. Participants will answer a 20-minute online survey about their health every 30 days. If participants are hospitalized, a family member or close friend will be asked to complete a brief 7-minute online survey about their hospital stay and treatment. Participants will be sent alerts and reminders throughout the study. Participation will last for 6 months. Type: Observational Start Date: Oct 2021 |
Respiratory Virus Sampling and Repository
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
COVID-19
Background:
Respiratory viruses, like the flu or COVID-19, cause significant illness and death
worldwide. Researchers want to collect samples from people with respiratory virus
infections. The samples in this natural history study will be used in future research.
Objective:
To obtain samples... expand
Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus infections. The samples in this natural history study will be used in future research. Objective: To obtain samples from people with respiratory viruses to learn more about respiratory virus infections and the immune responses against them. Eligibility: People aged 3 and older who have or are suspected to have a respiratory virus infection. Design: Participants will be screened with a medical record review. Participants will give blood samples. Data from their medical records will be collected. Participants will give nose samples. A soft plastic strip will be put into each nostril for a minute. They may also give nose, mouth (back of the throat), or saliva samples using swabs. Participants may receive kits by mail to collect nose and blood samples at home. They will use soft plastic strips to collect nose samples. To collect blood, they will prick their finger and dab a few drops of blood on four plastic tips. If a participant is in the hospital, air samples may be collected in their room. Participation will last for up to 2 years. After 2 years, participants may be asked for their consent again to give new samples and new medical data. Type: Observational Start Date: Aug 2022 |
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
Mayo Clinic
Long COVID
This study aims to assess the effects of both acute and chronic exposures to hypoxia and
hypercapnia in patients with Long COVID syndrome. expand
This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome. Type: Interventional Start Date: Sep 2024 |
A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
Pfizer
COVID-19
The purpose of the study is to learn about:
- how PF-07817883 is processed in the body of adult participants.
- the safety of PF-07817883.
These participants will have different levels of kidney function loss:
- moderate
- severe
- none or healthy Participants with moderate,... expand
The purpose of the study is to learn about: - how PF-07817883 is processed in the body of adult participants. - the safety of PF-07817883. These participants will have different levels of kidney function loss: - moderate - severe - none or healthy Participants with moderate, severe or no loss of kidney function may be taken into one of 3 groups. This study is seeking for participants who: - are male or female of 18 to 90 years of age. - have different levels of damage to kidney function or for one of the groups, no damage - are willing to follow the requirements of the study including stay at clinic for 5 nights and 6 days. About, 8 participants may be selected in groups 2 and 3. In group 1, around 8 to 12 participants may be selected. If participants agree to take part in the study, it may take up to 4 weeks to complete all the tests to confirm if they are fit to be in the study. If they seem to be fit for the study, participants will be admitted to a clinic research unit (CRU) at least 8 hours before dosing. On Day 1, participants will receive a single amount of study medicine (Day 1). A series of blood samples will be collected before and after giving medicines. Participants will be discharged from the CRU on Day 5. A follow-up phone call (or CRU visit, if needed), will occur 28-35 days after taking the medicine. The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks. Type: Interventional Start Date: Sep 2024 |
A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in...
ModernaTX, Inc.
SARS-CoV-2
The purpose of this study is to investigate the immunogenicity of mRNA COVID-19
variant-containing vaccine formulations against the vaccine matched variants and newly
emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
previously vaccinated adults. expand
The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults. Type: Interventional Start Date: Sep 2024 |
Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID
Mayo Clinic
Long COVID
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut
microbiome diversity of long-COVID subjects. expand
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut microbiome diversity of long-COVID subjects. Type: Interventional Start Date: Sep 2024 |
Improving Attention in Individuals With Long COVID-19
Shirley Ryan AbilityLab
Long Covid
This study is to find out if the Attention Processing Training program is a potential
treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating
the feasibility of completing this program virtually. expand
This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually. Type: Interventional Start Date: Mar 2024 |
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship...
Evidation Health
Influenza, Human
COVID-19
Influenza A
Influenza B
Respiratory Syncytial Virus (RSV)
The goal of this decentralized, observational study is to enroll and observe adults in
the contingent United States during the 2023-2024 flu season. The main study objectives
are to create a dataset of paired wearable data, self-reported symptoms, and respiratory
viral infection (RVI) from PCR testing... expand
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season. The main study objectives are to create a dataset of paired wearable data, self-reported symptoms, and respiratory viral infection (RVI) from PCR testing during the 2023-2024 flu season and to develop algorithm that is able to accurately classify asymptomatic and symptomatic RVI and understand the algorithm's performance metrics. Type: Observational Start Date: Jan 2024 |
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
SARS-CoV-2 Infection
COVID-19
The purpose of this clinical protocol is to learn about the safety, tolerability, and
immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of
SARS-CoV-2 in healthy people.
Substudy A:
- This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2... expand
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people. Substudy A: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1). - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Substudy B: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who are COVID-19 vaccine-naïve - who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration. - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Substudy C: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to: - Cohort 1: people who are 18 years of age and older, who will receive BNT162b2 (Omi JN.1), and, - Cohort 2: people who are 12 years of age and older, who will receive BNT162b2 (Omi JN.1), and, - Cohort 3: people who are 18 years of age and older who will receive BNT162b2 (Omi KP.2). - Participants may have never received a COVID-19 vaccine or, may have previously received COVID-19 vaccine(s), with the most recent dose received at least 150 days before the study vaccination (Visit 1). - The study is about 6 months long for each participant. - Participants will have at least 6 visits (Cohorts 1 and 3) or at least 5 visits (Cohort 2) to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Type: Interventional Start Date: Aug 2023 |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation...
University of Minnesota
COVID-19
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that
immune modulation can improve outcomes in hospitalized patients. This trial is designed
to determine whether intensification of immune modulation early in the course of the
disease (while patients are on low... expand
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement. Type: Interventional Start Date: Jul 2023 |
Immune Registry for Organ Transplantation From COVID Positive Donors.
Virginia Commonwealth University
COVID-19
Organ Transplant
The purpose of this study is to collect data generated by standard clinical practice to
determine the short term and long term clinical outcomes of recipients of solid organ
transplantation from COVID-19 infected donors and compare it to recipients with organ
transplant from COVID-19 negative donors. expand
The purpose of this study is to collect data generated by standard clinical practice to determine the short term and long term clinical outcomes of recipients of solid organ transplantation from COVID-19 infected donors and compare it to recipients with organ transplant from COVID-19 negative donors. Type: Observational [Patient Registry] Start Date: Dec 2022 |
Baby2Home (B2H) Mobile Health Application
Women and Infants Hospital of Rhode Island
COVID-19 Pandemic
Health Knowledge, Attitudes, Practice
Perinatal Depression
Mental Health Wellness
Post Partum Depression
The COVID-19 pandemic has transformed healthcare delivery; arguably, the fields of
obstetrics and pediatrics have experienced some of the greatest changes as they have
transitioned away from their role as a medical home and into more of an urgent care model
of care. Baby2Home is a digital health intervention... expand
The COVID-19 pandemic has transformed healthcare delivery; arguably, the fields of obstetrics and pediatrics have experienced some of the greatest changes as they have transitioned away from their role as a medical home and into more of an urgent care model of care. Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life. This randomized controlled trial will evaluate whether, compared to usual care, Baby2Home 1) improves maternal, paternal, and infant health service utilization outcomes over the first year postpartum, 2) improves maternal and paternal patient reported outcomes, and 3) reduces racial/ethnic and income-based disparities in preventive health services utilization and parental patient reported outcomes. Type: Interventional Start Date: Nov 2022 |
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older...
Pfizer
COVID-19
The purpose of this clinical trial is to learn about the safety and effects of the study
medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
Patients with COVID-19 who have more difficulty in fighting against infections have a
higher chance of severe illness. Such patients... expand
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19. Patients with COVID-19 who have more difficulty in fighting against infections have a higher chance of severe illness. Such patients may benefit from longer treatment durations compared to the standard treatment regimen. The study is seeking participants who: - Have a confirmed COVID-19 infection - Are Immunocompromised - Experience onset of signs/symptoms attributable to the current COVID-19 infection within 5 days prior to screening and ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization. In addition, this study will also evaluate the efficacy and safety of a second treatment course of nirmatrelvir/ritonavir in people who experience that their COVID-19 is flaring up within 14 days of having taken a 5-day treatment course of nirmatrelvir/ritonavir. For this group, the study is seeking participants who: - Have a confirmed COVID-19 infection - Experience a worsening of signs/symptoms after completing an initial 5-day course of nirmatrelvir/ritonavir - The worsening of COVID-19 symptoms must occur within 14 days after completion of the initial 5-day course of nirmatrelvir/ritonavir - Are Immunocompromised - Experience onset of signs/symptoms attributable to the current COVID-19 infection within 48 hours prior to screening and ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization. All participants will be taking the study medicine for either 5, 10, or 15 days. The study medication will be taken by mouth 2 times a day. Participants will take part in this study for about 24 weeks. The first dose of study medication is taken at the study site and the rest at home. Selected participants will need to visit the study site at least 10 times during the study. Type: Interventional Start Date: Aug 2022 |
IMM-BCP-01 in Mild to Moderate COVID-19
Immunome, Inc.
SARS-CoV2 Infection
COVID-19
The primary objective of this study is to evaluate the safety and tolerability of
intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
The secondary objectives of the study are to:
- Determine pharmacokinetics (PK) and evaluate viral clearance after single... expand
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: - Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. - Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Week 12. Type: Interventional Start Date: Jun 2022 |
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate...
Vitti Labs, LLC
COVID-19 Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome
Recent advances have been made in prevention of the viral infection via vaccines but
there is still need for effective treatment options for patients. Novel therapies need to
be developed to further improve clinical outcomes. The biggest medical challenge in the
response to COVID-19 is ARDS requiring... expand
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients. The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. . Type: Interventional Start Date: Mar 2025 |
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology...
University Hospitals Cleveland Medical Center
Post-acute COVID-19 Syndrome
Participants are being asked to take part in this research study because they have had a
previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent,
recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC). The
Investigators are interested in studying... expand
Participants are being asked to take part in this research study because they have had a previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent, recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC). The Investigators are interested in studying the effects of Vitamin K2 (MK-7) and Vitamin D3 supplementation on PASC symptoms and the underlying inflammatory process. Type: Interventional Start Date: Jun 2022 |
In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life
Massachusetts General Hospital
In Utero SARS-CoV-2 Exposure
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by
the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by
inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant
women have had a heightened prevalence... expand
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence and severity of infection. In this context, a new population of children has emerged who were exposed to maternal COVID-19 in the womb. As maternal diseases during pregnancy may impact the health of offspring over the life course, health outcomes among these individuals must be urgently evaluated. In the current study, the investigators will leverage a perinatal biorepository comprised of pregnant women with and without COVID-19 to delineate the metabolic and cardiovascular risk profiles of these offspring. This work stands to benefit the burgeoning population of children exposed to COVID-19 in the womb and to deepen the mechanistic understanding of developmental origins of cardiometabolic disease with respect to maternal infections. Type: Observational Start Date: Jun 2021 |
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress...
University of Minnesota
Covid19
SARS-CoV Infection
ARDS
ARDS, Human
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients
on mechanical ventilation. expand
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation. Type: Interventional Start Date: Jan 2025 |
Trial of Combination Therapy to Treat COVID-19 Infection
ProgenaBiome
COVID
Covid-19
Corona Virus Infection
Coronavirus Infection
Coronavirus-19
In this trial patients will be treated with either a combination of therapies to treat
COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6
months. expand
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months. Type: Interventional Start Date: Dec 2020 |
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
ProgenaBiome
COVID-19
Coronavirus Infection
Sars-CoV2
Corona Virus Infection
COVID
This is a Phase II interventional study testing whether treatment with
hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19 expand
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19 Type: Interventional Start Date: Jun 2020 |
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate
dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years
with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The
efficacy and safety of crizanlizumab... expand
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from the PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Phase II, multicenter, open-label study. Type: Interventional Start Date: Oct 2018 |
COVID-19 Self-testing IMPROVE
Temple University
COVID-19
The study aims to engage community partners to implement IMPROVE intervention and promote
(COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia
Area and New York City expand
The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City Type: Interventional Start Date: Jun 2023 |
Cardiopulmonary Exercise Tests in Patients With Long COVID
Sheffield Hallam University
Long COVID
COVID Long-Haul
The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings
has been established in the last decade. CPET methods remain highly relevant in the
COVID-19 endemic phase and should be used to assess those recovering from COVID-19
(SARS-CoV-2) infection. This diagnostic tool... expand
The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings has been established in the last decade. CPET methods remain highly relevant in the COVID-19 endemic phase and should be used to assess those recovering from COVID-19 (SARS-CoV-2) infection. This diagnostic tool could play an integral role in disease prognostication and evaluate the integrative response to incremental exercise. Date from such assessments can enable practitioners to characterise cardio-respiratory fitness and identify reasons for physical impairment or abnormal cardio-respiratory function. More than 50% of patients admitted to hospital will experience cardiorespiratory issues and significant morbidity during their recovery and will require significant rehabilitative support. In this context, measurements obtained from an assessment of cardio-respiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardio-respiratory function. Current approaches to rehabilitation are being developed on existing knowledge from Severe Acute Respiratory Syndrome (SARS) and Acute Respiratory Distress Syndrome (ARDS) related illness. These provide important insight but do not provide insight into the novel challenges provided by COVID-19. Type: Observational Start Date: Mar 2023 |
- Previous
- Next